Special Corporate Update WSCH
| Company Name |
Wasatch
Pharmaceuticals (OTCBB: WSCH) |
| Current Price |
$0.007 |
| 52-Week High |
$1.95 |
| 52-Week Low |
$0.0045 |
News from Wasatch Pharmaceutical (OTCBB: WSCH) is hard to come by lately. Gary Heesch,
CEO of Wasatch, doesn't buy the idea that a press release every day is productive. He feels "it is usually perceived as
an effort to over- promote the stock." But what about the future of WSCH? Why should anyone buy or hold their
stock with no news?
Mr. Heesch feels that past news releases and their record of Company accomplishments speak for
themselves. For example, Wasatch, now in its 18th year of research, has produced skin care products for the treatment
of most common skin disorders. This puts them years ahead of the competition.
In the last 12 months, WSCH has addressed a whole new dimension in preparation for launching its
products into the worldwide marketplace, so that millions of people will finally have access to therapies that allow them to
remedy their skin disorders and live more normal lives. This preparation involved:
(1) A new management team with
impressive individual records of creating billions of dollars in revenue for Oracle, Bausch & Lomb, and Warner
Lambert.
(2) The establishment of a new AISC Distribution Center that is fully inventoried with products ready for
shipment.
(3) Establishing beautiful corporate offices separate from the company's clinic.
(4) Relocation
of the American Institue of Skin Care clinic to a facility designed to be the prototype for future clinics.
To cap off
the last 12 months, patents were filed for five new products that will be packaged and ready for release to physicians and
hospitals this year. All of these accomplishments translate into a variety of activites and relationships that will
insure the growth and stability of WSCH.
When pressed to reveal this year's plans, Mr. Heesch wants to reserve the
substance of these activities until they are completed and tucked away. He did say that existing activities and plans
include the acquisition of existing medical clinics, ongoing discussion for foreign licensing, conversations with
groups of physicians that can represent as many as 2,000 physicians converting their patients to Wasatch products for their
skin care problems, and also a possible merger that will expand WSCH's sphere of influence in the medical
community.
As these activities come to fruition, they will be disclosed to WSCH shareholders and the
public in detail. Unlike many companies struggling with today's economy, Wasatch Pharmaceutical is alive and well and working
towards a productive future.
Stay tuned for plenty more to come from
WSCH.
DISCLAIMER:
Information within this email
contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the
Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations,
beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact
and may be "forward looking statements."
Forward looking statements are based on expectations, estimates and projections at
the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events
to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use
of words such as "projects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by
statements indicating certain actions "may," "could," or "might" occur. All information provided within this email
pertaining to investing, stocks, securities must be understood as information provided and not investment advice. Emerging Growth
Stock Alert advises all readers and subscribers to seek advice from a registered professional securities representative
before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as
any kind of investment advice.
In compliance with the Securities Act of 1933, Section17(b), Emerging Growth Stock Alert
discloses the receipt of ten million unrestricted shares of WSCH from a third party for the publication of this report and
additional services related to WSCH. Be aware of an inherent conflict of interest
resulting from such compensation due to our intent to profit from the sale of these shares. All factual information in
this report was gathered from public sources, including but not limited to SEC filings, Company Press Releases, and the company's
website at wasatchpharm.com. Emerging Growth Stock Alert believes this information to
be reliable but can make no guarantee as to its accuracy or completeness. Use of the material within this email constitutes your
acceptance of these terms.